This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at the HIV-1 specific CB8+T cell responses and the dominant HIV-1 genotype longitudinally among individuals identified as HLA-B*27, B*35, B*53, and/or B*57 positive through studies done in collaboration with the REACH project. Biomedical HIV-1 related data and samples are available for the time the subjects were enrolled in REACH. HIV-1 genotyping will certainly be possible from these retrospective samples and the stored PBMCs will be evaluated for usefulness in the HIV-1 specific assays. Prospectively, samples will be collected every six months over a two-year period to evaluate both HIV-1 specific CD8+T cell responses and the dominant HIV-1 genotype longitudinally. There is the potential to have data over a 9-10 year period depending on how long the subjects were enrolled in REACH. Sample Size: A total of 113 subjects were identified at former REACH/ATN clinical sites. A preliminary survey of the clinical sites estimates that about two-thirds of these subjects are still engaged in care and potentially available for this protocol. Population: Subjects who were identified as HLA Class 1 HLA-B*27, B*35, B*53, and/or B*57 positive from the REACH study will be contacted for their interest in participating in this study. Only former REACH sites in the ATN will be eligible to enroll subjects into this study. Duration: Subjects may be enrolled up to May 30, 2003, and will be followed for a total of 2 years (96 weeks). Primary Objective: Demonstrate that few CTL escape mutations occur in HIV-1 specific CB8+T cell epitopes that are HLA-B*27 abd B*57 restricted, when compared to those restriced by HLA-B*35 and B*53. Secondary Objective: Demonstrate that CD8+T cells have a high functional avidity to HLA-B*27 and B*57 bound epitopes when compared to those responding to HLA-B*35 and B*53 bound epitopes.
Showing the most recent 10 out of 211 publications
